Site Search Strategy Investor Relations At a glance Strategy QIAGEN is executing a focused strategy to build value through profitable growth opportunities in the expanding market for molecular analysis. We are a global leader in Sample to Insight solutions, with a portfolio of technologies to empower customers from start to finish in the molecular analysis process. In a challenging world, our approach is to help customers achieve molecular insights faster, better and more efficiently. Over more than three decades we have built a unique competitive advantage for QIAGEN: deep relationships with customers across the continuum from academic research, to pharmaceutical development, to molecular diagnostics and other applications. We partner with researchers in creating molecular testing technologies in the early stages, then develop and commercialize promising applications and platforms as these methods emerge in healthcare and industry. Our strategy contains a focus on 5 pillars of growth where we have novel technologies targeting >$6 billion in opportunities out of our >$11 billion total addressable market. In these areas we are aligning our investments to maximize sales in proven high-growth markets. QIAGEN’s 5 pillars of growth Sample technologies: Market leading portfolios of instruments and consumables for extracting nucleic acids (DNA, RNA, proteins) from samples in research and clinical workflows QIAcuity: Digital PCR platforms with ground breaking microplate technology backed by wide range of content QIAstat-Dx: Syndromic testing platform enabling rapid, accurate and comprehensive detection of a collection of pathogens in clinical settings NeuMoDx: Integrated PCR testing platforms for clinical testing labs with unparalleled ease of use QuantiFERON: The gold standard test for modern tuberculosis testing with unique automation capabilities We are investing in menu expansion of these systems to drive strong installed base growth and sustainable consumables sales. QIAGEN is committed to innovation in molecular testing, through cutting-edge R&D at our centres of excellence and targeted acquisitions that expand our presence in growing fields. QIAGEN is making a long-term difference in our world by making improvements in life possible. IR Contacts John Gilardi Vice President Head of Corporate Communications and Investor Relations Germany +49 2103 29 11711 U.S. +1 240 686 2222 The Netherlands +31 773 55 66 66 john.gilardi@qiagen.com Download VCARD Phoebe Loh Senior Director Investor Relations +49 2103 29 11457 phoebe.loh@qiagen.com Download VCARD Alexandra Koenig Investor Relations Coordinator +49 2103 29 11709 alexandra.koenig@qiagen.com Download VCARD Email Alerts Email Address SIGN UP Press Releases Events Presentations SEC-Filings End of Day Stock Quote Unsubscribe Follow Us linkedin open in new window facebook open in new window twitter open in new window youtube open in new window linkedin open in new window Contact Us call back mail BACK TO TOP This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Sample to Insight © QIAGEN 2013-21. All rights reserved Privacy Policy Trademarks & Disclaimers Accessibility Powered By Q4 Inc. 5.56.0.1 (opens in new window)